Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Type II granular corneal dystrophy (GCDII) is a rare form of stromal corneal dystrophy characterized by irregular-shaped well-demarcated granular deposits in the superficial central corneal stroma, and progressive visual impairment.
Features include always present findings: Reduced visual acuity, Visual impairment, and Lattice corneal dystrophy.
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 4:29 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Organ System
Phenotype Count |
|---|
Example Features |
|---|
Eyes | 2 | Visual impairment, Lattice corneal dystrophy |
TGFBI function has not been fully characterized.
Granular corneal dystrophy type II is associated with mutations in the TGFBI gene on chromosome 5.
Genetic testing for TGFBI is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 3 always present features.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for granular corneal dystrophy type II.
7 publications have been identified in PubMed for granular corneal dystrophy type II. Research spans Case Report / Case Series (50%), Basic Science / Preclinical (33%), and Gene Therapy / Novel Therapeutics (17%).
McLain A (2025). [PMID: 40185334](https://pubmed.ncbi.nlm.nih.gov/40185334/). *Journal of controlled release : official journal of the Controlled Release Society*. [Case Report / Case Series]
Min JS (2025). [PMID: 40556321](https://pubmed.ncbi.nlm.nih.gov/40556321/). *Ophthalmic genetics*. [Case Report / Case Series]
Yu Y (2025). [PMID: 40900077](https://pubmed.ncbi.nlm.nih.gov/40900077/). *Investigative ophthalmology & visual science*. [Basic Science / Preclinical]
Oztürk Ö (2024). [PMID: 39301332](https://pubmed.ncbi.nlm.nih.gov/39301332/). *Cureus*. [Case Report / Case Series]
Huang Y (2024). [PMID: 39959167](https://pubmed.ncbi.nlm.nih.gov/39959167/). *Molecular vision*. [Basic Science / Preclinical]
Azimi F (2024). [PMID: 40012800](https://pubmed.ncbi.nlm.nih.gov/40012800/). *Journal of current ophthalmology*. [Gene Therapy / Novel Therapeutics]